TabletsClinical Overview
Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally within 15 minutes before the start of each main meal (breakfast, lunch, dinner), or immediately with the meal with water. If a meal is skipped, the dose MUST be skipped. If an extra meal is added, an extra dose is taken.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia, mild headache, upper respiratory tract infection, nausea. Rare/Severe: Severe hypoglycemia, and transient liver dysfunction.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Take only with meals; skipping meals after taking repaglinide precipitates hypoglycemia. Contraindicated with gemfibrozil (gemfibrozil inhibits CYP2C8, increasing repaglinide levels eightfold and precipitating severe, prolonged hypoglycemia).
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Repaglinide Tablet 0.5mg
Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.
Repaglinide Tablet 2mg
Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.
Repaglinide 1mg + Metformin Hydrochloride (Sustained-release) 500mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Repaglinide 2mg + Metformin Hydrochloride (Sustained-release) 500mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).